ArticleBMC cancer2026
Single-cell and machine learning reveal ROS-associated heterogeneity in hepatocellular carcinoma for precision medicine.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReactive oxygen species (ROS) are critical regulators of tumor development and progression, yet their clinical significance and cellular mechanisms remain poorly defined in hepatocellular carcinoma (HCC).
methodsA comprehensive computational approach was employed to investigate ROS-related heterogeneity in HCC and to develop a prognostic model. Transcriptomic analyses at the bulk and single-cell levels were integrated to assess cellular differentiation, metabolic activity, and intercellular signaling. Machine learning techniques were applied to construct a clinically interpretable ROS signature, which was validated through laboratory experiments.
resultsAmong the two identified molecular clusters, the high-ROS subtype was characterized by enhanced immunosuppressive cell infiltration, hyperactivation of oncogenic signaling pathways, and poorer clinical outcomes. scRNA-seq analyses revealed that malignant cells exhibit significantly elevated ROS levels. High ROS expression in tumor cells was associated with enhanced intercellular communication, metabolic reprogramming, and a progressive deterioration of malignant phenotypes. The constructed prediction signature could reliably forecast prognosis, outperforming 49 previously published models. Moreover, it accurately delineated genetic heterogeneity, anticipated responses to targeted medicines, and identified pertinent clinical conditions. Inhibition of PFKP markedly reduced the proliferation and migration of HCC cells while inducing apoptosis.
conclusionThis study systematically delineates the molecular and cellular heterogeneity of ROS-associated subtypes in HCC, offering novel insights into precision medicine stratification and the development of targeted therapeutic strategies for ROS-driven malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.